Goutam Rath is Professor in the Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan, Bhubaneswar, India. His research focuses on nanotechnology-based systems for targeted drug and bioactive delivery, with applications in pharmaceutical development and healthcare. Prof. Rath has published extensively in peer-reviewed journals and has contributed to textbooks and book chapters in the fields of pharmaceutics and nanomedicine. His research has resulted in multiple patents, several of which have been transferred for commercial application. He supervises M.Pharm and Ph.D. researchers and serves on national expert panels and advisory groups related to biotechnology, nanomedicine, and pharmaceutical innovation. Goutam Ghosh is a professor at the School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan , Bhubaneswar, India. With over two decades of academic and research experience, his work focuses on the extraction, separation, and analysis of bioactive compounds from natural sources. His research spans herbal drug discovery and nanotechnology-based delivery systems targeting conditions such as diabetes, arthritis, malaria, cancer, and oxidative stress. He has authored more than 200 publications and has served as Investigator or Co-Principal Investigator on several nationally funded research projects supported by DBT and DST. His contributions to innovative pharmaceutical formulations, including nanofiber-based systems for cancer therapy, have significantly advanced translational medicine. Dr. Jindu Halder is Assistant Professor in the Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan, Bhubaneswar, India. His research focuses on the formulation and development of conventional and advanced drug delivery systems, including nanofibers, nanoparticles, and nanogels, with applications in the treatment of infectious diseases and cancer. His work spans pharmaceutical nanotechnology and translational therapeutics, with an emphasis on developing innovative delivery platforms to improve therapeutic outcomes.Prof. Halder has received research funding from national agencies, including DHR/ICMR, and has contributed to scholarly publications, book chapters, and intellectual property in the field of pharmaceutics. He has been involved in the development of novel drug delivery technologies, including nanofiber-based and mucoadhesive formulations, some of which have progressed toward commercial application through technology transfer initiatives. His academic and research activities continue to support innovation in pharmaceutical sciences and healthcare delivery.
